UPDATE: Piper Jaffray Raises PT on Cantel Medical on Continued Growth

In a report published on Thursday, Piper Jaffray analyst Thomas J. Gunderson raised the price target on

from $35 to $40 and maintained a rating of Overweight. In the report, Piper Jaffray stated, "We continue to like the investment opportunity for this infection control and protection set of businesses. CEO Krakauer has assembled a strong management team that we believe can keep the EPS growing (up 9% in this quarter; up 17% if not for the medical device tax) with further acquisitions, higher margin new products, and tight expense controls." Cantel Medical closed on Thursday at $34.09.